Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. General Biologicals's annualized net income for the quarter that ended in Dec. 2025 was NT$1,189.3 Mil. General Biologicals's average shareholder tangible equity for the quarter that ended in Dec. 2025 was NT$461.1 Mil. Therefore, General Biologicals's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 257.89%.
The historical rank and industry rank for General Biologicals's Return-on-Tangible-Equity or its related term are showing as below:
ROCO:4117'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -79.62 Med: -44.81 Max: 121.25
Current: 121.25
During the past 13 years, General Biologicals's highest Return-on-Tangible-Equity was 121.25%. The lowest was -79.62%. And the median was -44.81%.
ROCO:4117's Return-on-Tangible-Equity is ranked better than 92.88% of 899
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs ROCO:4117: 121.25
General Biologicals (ROCO:4117) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
General Biologicals Return-on-Tangible-Equity Related Terms
General Biologicals Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for General Biologicals's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
General Biologicals Return-on-Tangible-Equity Chart
ROCO:4117 vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, General Biologicals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
General Biologicals Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, General Biologicals's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where General Biologicals's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 257.89% mean?
General Biologicals (ROCO:4117) has a Return-on-Tangible-Equity of 257.89% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on General Biologicals and its competitors. According to the industry distribution chart, General Biologicals ranks #64 out of 899 companies in the Drug Manufacturers industry, placing it in the top 7.1%.
Is General Biologicals' Return-on-Tangible-Equity too high?
General Biologicals' current Return-on-Tangible-Equity is 257.89%. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. General Biologicals' value of 257.89% is 3164.4% above this industry median. Based on the distribution chart, General Biologicals ranks #64 out of 899 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, General Biologicals has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does General Biologicals' Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, General Biologicals ranks #64 out of 899 companies for Return-on-Tangible-Equity. This places General Biologicals in the top 7% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.90. General Biologicals' value of 257.89% is 3164.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 899 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. General Biologicals's current Return-on-Tangible-Equity of 257.89% is 3164.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on General Biologicals and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. General Biologicals's current Return-on-Tangible-Equity is 257.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is General Biologicals stock overvalued right now?
Based on GuruFocus' analysis, General Biologicals (ROCO:4117) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$14.04, compared to a current price of NT$10.55 — trading 24.9% below its estimated fair value. The current Return-on-Tangible-Equity is 257.89% and 3164.4% above the Drug Manufacturers industry median of 7.90. General Biologicals' overall GF Score™ is 50/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For General Biologicals (ROCO:4117), the current Return-on-Tangible-Equity is 257.89% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is General Biologicals (ROCO:4117) Overvalued in 2026?
Based on GuruFocus' analysis, General Biologicals stock appears to be undervalued.
The current stock price of NT$10.55 is trading 24.9% below its estimated GF Value™ of NT$14.04.
GuruFocus considers General Biologicals to be Modestly Undervalued.
Key valuation signals for ROCO:4117:
Return-on-Tangible-Equity: 257.89%
GF Value™: NT$14.04 vs. price of NT$10.55 (24.9% below fair value)
Industry Position: 3164.4% above the Drug Manufacturers median (#64 of 899)
No single metric tells the full story. See the ROCO:4117 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
General Biologicals Corp is a developer and manufacturer of vitro diagnostic devices in Taiwan. It offers research development, marketing and servicing of products and solutions for hospitals, medical laboratories, blood banks, and research and industry. Its products include Anti-HDV, HIV Ag-Ab COMB, Anti-HBs, and many others.
50GF Score
Get the complete analysis for ROCO:4117
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4117 has been successfully added to your 
